Curanex Pharmaceuticals Inc announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $4.00 per share, totaling gross proceeds of $15 million.
The IPO is being conducted on a firm commitment basis.
The Company's shares will begin trading on the Nasdaq Capital Market under the ticker symbol 'CURX' on August 26, 2025.
Public Offering Details
3,750,000 shares priced at $4.00 per share, raising $15 million.
Use of Proceeds
Funds will be used for the development of lead product candidate Phyto-N and other corporate purposes.
Underwriters and Counsel
Dominari Securities LLC is the lead underwriter, supported by Pacific Century Securities LLC and Revere Securities LLC. Legal counsel is provided by Crone Law Group, P.C. and Sichenzia Ross Ference Carmel LLP.
- Curanex Pharmaceuticals Inc focuses on developing botanical drugs for inflammatory diseases, with leading candidate Phyto-N targeting ulcerative colitis.
- The successful IPO will provide funding for essential FDA studies, IND submission, and Phase I clinical trials for Phyto-N.
Curanex Pharmaceuticals Inc's IPO pricing marks a crucial milestone in its journey towards developing novel botanical drugs for inflammatory diseases. The funding secured will drive the advancement of Phyto-N, positioning the company for significant growth in the pharmaceutical sector.